Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This case report describes a 54-year-old woman with familial dyskeratotic comedones who experienced slight improvement in her skin lesions after three months of treatment with topical retinoids and urea cream.

This study found that overexpression of the enzyme ornithine decarboxylase in transgenic mice led to UVB-induced skin tumors, but this was prevented by the ODC inhibitor α-difluoromethylornithine.

In this study, Urtica dioica extract was found to significantly downregulate 5-alpha-reductase type II gene expression in skin cells, suggesting potential usefulness against androgenic skin diseases.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This case report describes an instance of autosomal recessive uncombable hair syndrome caused by maternal uniparental disomy of chromosome 1.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

This case report describes a unilateral contact dermatitis caused by shoe dye containing 4-aminoazobenzene, which was confirmed with patch testing, highlighting its atypical presentation.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

This case report describes the first known occurrence of urticaria pigmentosa in a domestic shorthair cat, where oral dexamethasone and cetirizine hydrochloride offered effective management following a comprehensive diagnostic work-up.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This study found that long-term use of difluprednate ophthalmic emulsion in dogs can lead to HPA axis suppression and potentially cause iatrogenic hyperadrenocorticism, with localized alopecia suspected due to dermal absorption.

This case report describes a 62-year-old woman diagnosed with undifferentiated connective tissue disease and renal amyloidosis, presenting symptoms like joint pain, Raynaud's phenomenon, and carpal tunnel syndrome.

This study identified UBC22 as a novel E2 enzyme responsible for Lys11-linked ubiquitination in Arabidopsis, revealing its crucial roles in seed setting, female gametophyte development, and pathogen resistance.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

In this study, researchers found a significant association between attention-deficit/hyperactivity disorder stimulant medications and alopecia universalis in children, although this finding was based on a small sample size.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This review discusses diffuse unpatterned alopecia (DUPA) as an understudied variant of androgenetic alopecia, summarizing its presentation and management while calling for further research to better understand its distinct characteristics.

This study found that inhibiting the enzyme ornithine decarboxylase (ODC) prevented UVB-induced basal cell carcinomas in a mouse model, suggesting ODC is a potential target for chemoprevention strategies.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This letter discusses the use of UVA-1 in the treatment of alopecia areata but reports no new clinical results.

This case report describes a patient in whom vitiligo was induced by diphenylcyclopropenone treatment for alopecia universalis, highlighting the potential overlap of susceptibility genes between the two conditions.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.